TB-500 is sold across grey-market vendors as a fast-track tissue-repair peptide, built on real cell biology involving actin sequestration and angiogenesis. It also entered human wellness circles by way of a veterinary doping scandal, not a clinical development program, and as of 2026 has never completed a published human trial for any indication.
Tb-500
-
TB-500 and the Thymosin Beta-4 Evidence Gap